Monitoring woman taking tamoxifen;Comment surveiller une femme sous tamoxifene

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 27, Issue 3, 1998, Pages 285-289

  Lansac, J ^a   Diouf, A ^a  

^a CHU BRETONNEAU   (France)

Author keywords

Breast cancer; Endometrial cancer; Side effects; Tamoxifen

Indexed keywords

TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER SURVIVAL; DRUG EFFECT; DRUG MONITORING; ENDOMETRIUM CANCER; FEMALE; HUMAN; METRORRHAGIA; PATIENT MONITORING; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG MONITORING; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; RISK FACTORS; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 0031799960     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Assikis VJ, Neven P, Jordan VC. A realistic clinical perspective of Tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32A:1464-76.
2. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy.133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 Women. Lancet 1992;339:71-85.
3. Cartson RW. Scientific review of tamoxifen.Overview from a medical oncologist. Semin oncol 1997;24:1-7.
4. Colletta AA, Benson JR, Baum M. Alternative mechanisms of action of anti-œstrogens. Breast cancer. Res Treat 1994;31:5-9.
5. Love RR, Mazess RB, Barden HS. Effects of Tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
6. Kristinsen B, Ejlersten B, Dalgaard P. Tamoxifen and bone metabolism in postmenopausal low risk breast cancer patients : a randomized study. J Clin Oncol 1994;12:992-7.
7. Bilimoria MM, Assikis VJ, Jordan VC. Should adjuvant tamoxifen therapy be stopped at 5 years ? Cancer J Sci Am 1996;2:140-50.
8. Boccardo F, Guamer D, Rubagotti A. Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 1984;70:61-8.
9. Mc Donald CC, Alexander FE, Whyte BW. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br J Med 1995;311: 977-80.
10. Neven P, De Muylde X, VanBelle Y. Tamoxifen and the uterus and endometrium. Lancet 1989;i:375.
11. Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet 1995;49:241-57.
12. Sananes S, Khairallah T, Touboul E. Surveillance des patientes traitées par tamoxifène. Presse Med 1996;25: 499-502.
13. Touboul. E, Uzan S, Schlienger M. Hormonothérapie des cancers du sein. J Obstet Gynecol 1994;2:225-32.
14. Jordan VC, Fritz NF, Tomey DC. Long term adjuvant therapy with tamoxifen effects on sex hormon binding globulin and antithrombin III. Cancer Res 1987;47:4517-9.
15. Lipton A, Harvey HA, Hamilton RV. Venous thrombosis: a side effect of Tamoxifen treatment. Cancer Treat Rep 1979;63:1833-4.
16. Fisher B, Constantino J, Redmond C. A randomised clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have oestrogen-receptor positive tumors. N Engl J Med 1989;320:479-84.
17. Rudquist LE. Long term toxicity of Tamoxifen. Recent Results Cancer Res 1993;127:257-66.
18. Longstaff S, Sigurdsson H, O' Keefe.M. A control study of the ocular effects of Tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 1989;25:1805-8.
19. Pavidis NA, Petris C, Brassoulis E. Clear evidence that long term, low dose Tamoxifen treatment can induce ocular toxicity. Cancer 1992;69:2961-4.
20. Cohen I, Beyth Y, Tepper R. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen : a new entity? Gynecol Oncol 1995;58:86-91.
21. Cohen I, Rosen DJ, Shapira J. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993;100:567-70.
22. Dauplat J, Le Bouedec G, Achard JL. Adénocarcinome de l'endomètre chez deux patientes prenant du tamoxifène. Presse Med 1990;19:380-1.
23. Formander T, Rudquist LE, Cedemark B. Adjuvant Tamoxifen in early Breast cancer occurrence of new primary cancers. Lancet 1989;1:117-9.
24. Friedl A, Jordan VC. What do we know and what don't we know about tamoxifen in the human uterus. Breast cancer Res Treat 1994;31:27-39.
25. Le Bouedec G, Pingeon JM, Fondrinier. Surveillance gynécologique des traitements du cancer du sein par le tamoxifène. Rev Fr Gynecol Obstet 1995;90:379-82.
26. Exacoustos C, Zupi E, Cangi B. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen : an ultrasound, colour flow Doppier, hysteroscopic and histological study. Ultrasound Obstet Gynecol 1995;6:435-42